Side-by-side comparison of AI visibility scores, market position, and capabilities
Antiviral biopharma with $28.6B FY2024 revenue; Biktarvy $14B HIV franchise; lenacapavir 99%+ HIV prevention efficacy in 2024 trials is landmark breakthrough; Trodelvy oncology expansion.
Gilead Sciences is a biopharmaceutical company specializing in antiviral medicines, oncology, and inflammatory diseases, founded in 1987 and headquartered in Foster City, California, trading on Nasdaq (GILD). The company reported approximately $28.6 billion in total revenues for FY2024 under CEO Daniel O'Day, driven by the world's leading HIV treatment franchise anchored by Biktarvy—the world's best-selling antiretroviral therapy with over $14 billion in annual global sales—along with Veklury (remdesivir) for COVID-19 treatment, and a growing oncology portfolio including Trodelvy (sacituzumab govitecan, an ADC for breast and bladder cancer), Yescarta, and Tecartus (CAR-T cell therapies). Gilead's 2024 HIV prevention breakthrough—lenacapavir, a twice-yearly injection preventing HIV infection with near-100% efficacy in large clinical trials—represents potentially the most important HIV prevention advance since the development of daily oral PrEP.
Thermo Fisher (TMO) reported $42.9B revenue in FY2024, down 1% YoY. World's #1 life sciences company. Serves pharma, biotech, labs globally. ~100,000 employees. HQ: Waltham, MA.
Thermo Fisher Scientific Inc. is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services to researchers, healthcare organizations, and industrial companies. Headquartered in Waltham, Massachusetts, Thermo Fisher was formed through the 2006 merger of Thermo Electron and Fisher Scientific and has since grown aggressively through acquisitions. The company reported revenues of $42.9B in FY2024, slightly down year-over-year after exceptional COVID-related revenue in 2021–2022.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.